Carna Biosciences Inc
TSE:4572
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Carna Biosciences Inc
TSE:4572
|
5.6B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
213.3B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.5B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.9B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
273.1B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.5B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.9B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.6B USD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Carna Biosciences Inc
Glance View
Carna Biosciences, Inc. engages in the drug discovery business. The company is headquartered in Kobe, Hyogo-Ken and currently employs 64 full-time employees. The company went IPO on 2008-03-25. The firm operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Carna Biosciences Inc is -402.2%, which is below its 3-year median of -215.5%.
Over the last 3 years, Carna Biosciences Inc’s Net Margin has decreased from -6.1% to -402.2%. During this period, it reached a low of -402.2% on Oct 30, 2025 and a high of -6.1% on Aug 30, 2022.
